Benefit–Cost Evaluation of Obesity Treatments

WSIPP is partnering with the Washington State Office of the Insurance Commissioner to evaluate the monetary benefits and costs of selected obesity treatments. Using a meta-analytic approach, WSIPP will assess the effectiveness of interventions such as bariatric surgery, FDA-approved weight-loss medications (GLP-1s), and behavioral or lifestyle programs. The analysis will translate impacts on outcomes like obesity, weight loss, and diabetes into monetary terms using WSIPP’s benefit–cost model, providing policymakers with clear, evidence-based insights.

The project will be completed in September 2026.
Morgan Spangler, (360) 664-9807